CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2070.0
(-1.66%)
KRW 2070.0
(-1.66%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 93.9 Billion KRW | 14.25% |
| 2022 | 82.19 Billion KRW | 18.31% |
| 2021 | 69.47 Billion KRW | 7.78% |
| 2020 | 64.45 Billion KRW | 27.03% |
| 2019 | 50.74 Billion KRW | 943.0% |
| 2018 | 4.86 Billion KRW | 8.68% |
| 2017 | 4.47 Billion KRW | 14.65% |
| 2016 | 3.9 Billion KRW | -13.26% |
| 2015 | 4.5 Billion KRW | 9.56% |
| 2014 | 4.1 Billion KRW | 27.8% |
| 2013 | 3.21 Billion KRW | 17.7% |
| 2012 | 2.73 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 24.85 Billion KRW | 8.94% |
| 2024 Q1 | 22.81 Billion KRW | 3.78% |
| 2023 Q2 | 25.43 Billion KRW | 10.8% |
| 2023 FY | 93.9 Billion KRW | 14.25% |
| 2023 Q4 | 21.98 Billion KRW | -6.61% |
| 2023 Q1 | 22.95 Billion KRW | 5.32% |
| 2023 Q3 | 23.53 Billion KRW | -7.45% |
| 2022 Q3 | 2.22 Billion KRW | 0.31% |
| 2022 FY | 82.19 Billion USD | 18.31% |
| 2022 Q4 | 21.79 Billion KRW | 881.65% |
| 2022 Q2 | 2.21 Billion KRW | 9.54% |
| 2022 Q1 | 2.02 Billion KRW | 3.06% |
| 2021 Q1 | 1.74 Billion KRW | 8.33% |
| 2021 FY | 69.47 Billion USD | 7.78% |
| 2021 Q2 | 1.89 Billion KRW | 8.67% |
| 2021 Q3 | 1.95 Billion KRW | 3.16% |
| 2021 Q4 | 1.96 Billion KRW | 0.43% |
| 2020 Q3 | 1.6 Billion KRW | 17.34% |
| 2020 Q1 | 1.41 Billion KRW | -2.04% |
| 2020 Q2 | 1.36 Billion KRW | -3.26% |
| 2020 FY | 64.45 Billion USD | 27.03% |
| 2020 Q4 | 1.6 Billion KRW | 0.39% |
| 2019 Q2 | 1.43 Billion KRW | 9.63% |
| 2019 Q4 | 1.44 Billion KRW | 2.6% |
| 2019 Q1 | 1.3 Billion KRW | 6.79% |
| 2019 Q3 | 1.4 Billion KRW | -2.13% |
| 2019 FY | 50.74 Billion USD | 943.0% |
| 2018 FY | 4.86 Billion USD | 8.68% |
| 2018 Q4 | 1.22 Billion KRW | 0.0% |
| 2018 Q3 | 1.22 Billion KRW | -3.28% |
| 2018 Q2 | 1.26 Billion KRW | 10.29% |
| 2018 Q1 | 1.14 Billion KRW | 3.45% |
| 2017 Q1 | 1.06 Billion KRW | 3.31% |
| 2017 Q2 | 1.16 Billion KRW | 9.41% |
| 2017 Q3 | 1.12 Billion KRW | -3.53% |
| 2017 FY | 4.47 Billion USD | 14.65% |
| 2017 Q4 | 1.11 Billion KRW | -1.59% |
| 2016 FY | 3.9 Billion USD | -13.26% |
| 2016 Q4 | 1.03 Billion KRW | -0.23% |
| 2016 Q3 | 1.03 Billion KRW | 3.87% |
| 2016 Q2 | 998.38 Million KRW | 19.64% |
| 2016 Q1 | 834.45 Million KRW | -16.35% |
| 2015 Q2 | 1.19 Billion KRW | 9.98% |
| 2015 Q1 | 1.08 Billion KRW | 1.8% |
| 2015 FY | 4.5 Billion USD | 9.56% |
| 2015 Q4 | 997.5 Million KRW | -18.03% |
| 2015 Q3 | 1.21 Billion KRW | 1.6% |
| 2014 Q4 | 1.06 Billion KRW | -1.33% |
| 2014 Q3 | 1.08 Billion KRW | 3.25% |
| 2014 Q2 | 1.05 Billion KRW | 16.14% |
| 2014 Q1 | 904.16 Million KRW | 7.11% |
| 2014 FY | 4.1 Billion USD | 27.8% |
| 2013 Q1 | 726.75 Million KRW | 3.95% |
| 2013 FY | 3.21 Billion USD | 17.7% |
| 2013 Q3 | 826.9 Million KRW | 1.24% |
| 2013 Q2 | 816.78 Million KRW | 12.39% |
| 2013 Q4 | 844.14 Million KRW | 2.08% |
| 2012 Q4 | 699.16 Million KRW | 0.0% |
| 2012 FY | 2.73 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | 30.927% |
| Celltrion Pharm, Inc. | 388.79 Billion KRW | 75.847% |
| Huons Global Co., Ltd. | 758.37 Billion KRW | 87.617% |
| DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 87.154% |
| Enzychem Lifesciences Corporation | 76.03 Billion KRW | -23.498% |
| Humedix Co., Ltd. | 152.27 Billion KRW | 38.33% |
| Boditech Med Inc. | 134.21 Billion KRW | 30.035% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | -35.379% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | -572.298% |
| Huons Co., Ltd. | 552 Billion KRW | 82.988% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | -15.938% |
| AptaBio Therapeutics Inc. | 323.86 Million KRW | -28895.281% |